Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Fintzi

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2022
Discovering disease-causing pathogens in resource-scarce Southeast Asia using a global metagenomic pathogen monitoring systemJennifer A Bohl, Sreyngim Lay, Sophana Chea, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
NEJM Evidence|June 24, 2025
A Vaccine to Block <i>Plasmodium falciparum</i> TransmissionSara A Healy, Issaka Sagara, Mahamadoun H Assadou, et al.
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
The Lancet. Infectious Diseases|July 27, 2023
Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trialIssaka Sagara, Sara A Healy, Mahamadoun H Assadou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
JCI Insight|November 24, 2020
An immune-based biomarker signature is associated with mortality in COVID-19 patientsMichael S Abers, Ottavia M Delmonte, Emily E Ricotta, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2022
Discovering disease-causing pathogens in resource-scarce Southeast Asia using a global metagenomic pathogen monitoring systemJennifer A Bohl, Sreyngim Lay, Sophana Chea, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
NEJM Evidence|June 24, 2025
A Vaccine to Block <i>Plasmodium falciparum</i> TransmissionSara A Healy, Issaka Sagara, Mahamadoun H Assadou, et al.
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
The Lancet. Infectious Diseases|July 27, 2023
Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trialIssaka Sagara, Sara A Healy, Mahamadoun H Assadou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
JCI Insight|November 24, 2020
An immune-based biomarker signature is associated with mortality in COVID-19 patientsMichael S Abers, Ottavia M Delmonte, Emily E Ricotta, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Pageof 4